International Paper Company Common Stock vs Novo Nordisk A/S — how do they compare? International Paper Company Common Stock trades at $32.09 (market cap $16.85B), while Novo Nordisk A/S trades at $37.79 (market cap $169.08B). The key difference: Novo Nordisk A/S is far larger — about 10× International Paper Company Common Stock's market cap, and International Paper Company Common Stock pays the higher dividend (5.82%). Which is the better fit depends on your goals — on Pluang, investors hold International Paper Company Common Stock for 0 Days and Novo Nordisk A/S for 116 Days on average.
| IP | NVO | |
|---|---|---|
Market Cap | $16.85B | $169.08B |
Volume | 3,482,586 | 9,259,152 |
Sector | Basic Materials | Health |
52-Week High | $49.19 | $63.98 |
52-Week Low | $29.38 | $35.29 |
Typical Hold Time | 0 Days | 116 Days |
Enterprise Value | $25.81B | $183.28B |
Dividend Yield | 5.82% | 4.72% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novo Nordisk (NVO) trades at $38.12, down 1.19% with bearish technical signals despite strong fundamentals. The company reported Q2 2026 EPS of $0.96, beating expectations by 17%, continuing a trend of earnings outperformance. Valuation metrics remain attractive with P/E of 9.67 and ROE of 59.82%, while recent news highlights pipeline expansion through $4 billion in licensing deals and progress on oral Wegovy formulations.
The stock presents a compelling value opportunity with strong profitability and growth prospects in obesity/diabetes markets, though technical weakness and competitive pressure from Eli Lilly create near-term headwinds. Analyst consensus remains bullish with $42.33 price target representing 11% upside potential from current levels.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
International Paper Company is a US producer of fiber-based packaging, pulp, and paper products, manufacturing corrugated packaging and containerboard used to ship and protect goods.
Read more on IP →With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →